Skip to main content
. 2022 Jun 21;2022(6):CD006404. doi: 10.1002/14651858.CD006404.pub4

4.1. Analysis.

4.1

Comparison 4: Pyronaridine‐artesunate versus other antimalarials for all malaria subtypes (safety outcomes only), Outcome 1: Serious adverse events